[헬스코리아뉴스 / 이상훈] The KOSPI ended with a drop of more than 1% due to an offensive selling by institutions and foreigners. Individuals bought 2 trillion won worth of money to defend the index, but it was not enough.
On the 4th, the KOSPI index closed at 3043.49, down 39.50 points (-1.28%) from the previous day. It was foreigners and institutions that led the downtrend. They net sold 9325 billion won and 1,283.2 billion won, respectively. Individuals net bought 2,1984 billion won.
Most of the sectors, excluding some sectors such as steel and non-metallic minerals, showed a decline. The pharmaceutical index fell 172.24 points (-0.94%) compared to the previous day to 11,8163.94.
Chong Kun Dang (+6.59%), Orient Bio (+5.48%), United Pharm (+3.56%), Chong Kun Dang Bio (+3.41%), Chong Kun Dang Holdings (+1.91%), and Hyundai Pharm (+1.90%) Mainly climbed.
Chong Kun Dang’s uptrend is due to expectations for COVID-19 treatment. Chong Kun Dang, which is competing with other pharmaceutical companies for the No. 2 spot for the domestically developed Corona 19 treatment, is said to be applying for conditional approval for the Corona 19 treatment sooner or later.
On the other hand, both Ilyang Pharm and Ilyang Pharm, which failed in phase 3 clinical trials of the new drug, fell sharply as they recorded the lower limit. This is attributed to the failure of phase 3 clinical trials of’Supect (ingredient name Radotinib)’, a leukemia treatment that sought to expand indications as a COVID-19 treatment.
Following this, Bukwang Pharmaceutical (-9.76%), Samsung Pharmaceutical (-6.25%), Shinpoong Pharmaceutical (-4.26%), and Shinpoong Pharmaceutical (-4.18%) continued to decline. The weakness of Bukwang Pharmaceutical is largely attributable to the announcement of an unfaithful disclosure corporation. On April 1 of last year, Bukwang Pharmaceutical corrected the signing of a single sale and supply contract, but only announced the correction on the 2nd.
Meanwhile, the KOSDAQ recorded 926.20, down 4.60 points (0.49%) from the previous day, and the pharmaceutical index fell 158.74 points (-1.36%) to 10,1482.71.
ISU Abgis recorded a double-digit increase rate (+13.01%), followed by Cell Biotech (+3.61%), T&R Biofab (+2.44%), Binex (+2.34%), Celltrion Pharmaceutical (+2.15%), and National Pharmaceutical Co., Ltd. (+1.72%) and the like showed an uptrend compared to the previous day.
On the other hand, stocks such as Samcheondang Pharmaceutical (-6.50%), Gencurix (-6.17%), Hwail Pharmaceutical (-6.01%), Huzel (-5.21%), Sewoon Medical (-5.19%), and Oscotek (-5.00) declined. I closed the house.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited